Last reviewed · How we verify
latanoprost/timolol fixed combination drops
Latanoprost reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor, while timolol decreases aqueous humor production via beta-adrenergic blockade.
Latanoprost reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor, while timolol decreases aqueous humor production via beta-adrenergic blockade. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | latanoprost/timolol fixed combination drops |
|---|---|
| Sponsor | Aristotle University Of Thessaloniki |
| Drug class | Prostaglandin analog / Beta-blocker combination |
| Target | Prostaglandin F receptor (FP receptor) / Beta-adrenergic receptors (β1 and β2) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Latanoprost is a prostaglandin F analog that binds to prostaglandin F receptors on the ciliary muscle, promoting drainage of fluid from the eye through the unconventional uveoscleral pathway. Timolol is a non-selective beta-blocker that reduces aqueous humor secretion by the ciliary body. The combination provides additive intraocular pressure-lowering effects through complementary mechanisms.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Iris pigmentation increase
- Eyelash growth (hypertrichosis)
- Eye irritation/discomfort
- Headache
- Bradycardia
- Bronchospasm (in susceptible patients)
Key clinical trials
- Effect of IOP Lowering on Progressive HM (NA)
- Long Term Use Of Xalacom In Patients Glaucoma Or Ocular Hypertension
- 24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration. (PHASE4)
- Switching From the Preserved to the Preservative - Free Latanoprost - Timolol FC in Glaucoma Patients With OSD (NA)
- A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients (PHASE3)
- A Study of Glaucoma or Ocular Hypertension in Patients Within the United States (PHASE3)
- 24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations (PHASE4)
- 24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: